Need Help? 0800 34 24 66
For country-specific search results please log in above

NanoString Technologies

 
 
NanoString 1018
  • Better, faster results with less effort than qPCR or arrays
  • Accurately target regions of interest
  • Lowest hands-on time of any platform on the market
  • Profile up to 800 regions of the human genome in a single reaction
 
CNV & Karyotyping PAM50-based Breast Cancer Test
 
 
NANOU 2110-150px
Introducing NanoString University (NanoU) an On-Demand Resource Portal
NanoU features course offerings ranging from self-guided videos as well as instructor led live & interactive courses.

Create your profile today for full access to all training material.
Register >
 
CNV & Karyotyping
nCounter CNV CodeSets provide superior accuracy and reproducibility for studies of all sizes. Achieve better results faster and with substantially less effort than with qPCR or arrays.
 
Simplified Workflow Delivers Gold-Standard Data, Faster
With the lowest hands-on time of any copy number variation (CNV) analysis platform, the nCounter Analysis System is ideal for studies in which large numbers of samples must be tested. Built on NanoString’s unique digital detection technology, nCounter CNV CodeSets provide superior accuracy and reproducibility for studies of all sizes. With nCounter CNV CodeSets, you can achieve better results, faster, and with substantially less effort than qPCR or arrays.
 
High Quality Data Delivered in A Simple Workflow
The CNV CodeSet workflow requires the least hands-on time of any platform commonly used for CNV analysis. In less than 25 minutes you can set up 12 reactions with no technical replicates required. And it’s simple. Just fragment your DNA and set up the hybridization – the rest is automated.
PAM50-based Breast Cancer Test
NanoString Technologies obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the company to sell its test in the European Union and other countries recognizing the CE Mark.
 
NanoString’s test provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy. Together with studies from the literature, this information has been shown to convey valuable information about a patient’s prognosis that can inform critical decisions about the patient’s course of therapy.